Local lnterferon-Alpha2b Is Not an
Effective Treatment in Early-Stage
Peyronie's Disease

Wegner, H; Andresen, Reimer; Knispel, Helmut H.; Miller, Kurt

doi:10.1159/000480857

Cited by 52 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They can be effectively treated with non-steroidal antiinflammatory drugs before interferon injection. 34 Further studies are needed to better compare its safety and efficacy compared to other treatments and to assess its functional significance for patients.…”

Section: Intralesional Interferon-α2bmentioning

confidence: 99%

Peyronie’s Disease: Recent Treatment Modalities

Albaz¹,

Üçer²

2017

EMJ

View full text Add to dashboard Cite

Peyronie’s disease (PD), which is characterised by fibrous plaque formation in the tunica albuginea of the penis, is associated with pain, erectile dysfunction, and anatomical malformations that negatively affect the quality of life of afflicted men. The optimum medical therapy for PD has not yet been identified. In the last 5 years, commonly used oral medications have been replaced by intralesional therapies. Intralesional collagenase Clostridium histolyticum is the only US Food and Drug Administration (FDA) approved treatment for PD. Minimally invasive intralesional therapies and surgical intervention form the basis of contemporary therapy for this disorder. These therapeutic options, along with selected portions of the guidelines, are explored in this review. The objective is to describe the current state of practice for each of the most commonly used, as well as several developing, treatment modalities of PD.

show abstract

Section: Intralesional Interferon-α2bmentioning

confidence: 99%

Peyronie’s Disease: Recent Treatment Modalities

Albaz¹,

Üçer²

2017

EMJ

View full text Add to dashboard Cite

show abstract

“…Interferons -In 1991, Duncan et al [42] reported that IFNs decrease the rate of proliferation of fibroblasts in Peyronie's plaques in vitro, reduce the production of extracellular collagen, and increase the activity of collagenase. Initial studies performed by Wegner et al [43,44] demonstrated low rates of improvement, but a high incidence of side effects, including myalgias and fever. In 1999, Ahuja et al [45] reported on 20 men who received 1 × 10 6 units of IFN-α-2b biweekly for 6 months.…”

Section: Intralesional Therapiesmentioning

confidence: 99%

Peyronie's Disease: Evaluation and Review of Nonsurgical Therapy

Abern

Levine

2009

The Scientific World JOURNAL

View full text Add to dashboard Cite

The purpose of our study was to outline the evaluation of the Peyronie's disease (PD) patient and review the available nonsurgical treatments. A review of the literature on oral, intralesional, external energy, iontophoresis, and mechanical therapies for PD was performed. PubMed was utilized to find all published articles, and several meeting abstracts were reviewed for data ahead of publication. Our medical evaluation of the PD patient is described. The published results of available treatment options are reviewed, with recommendation by the authors for appropriate nonsurgical management of PD. There are no available validated questionnaires for PD, but a thorough history and focused physical examination, including measurement of erect penile deformity, will help the clinician make the diagnosis and guide treatment options. Although there are many published reports that show efficacy of nonsurgical therapies for PD, there is a lack of large-scale, multicenter, controlled clinical trials, which makes treatment recommendations difficult. Careful review of the literature does suggest that there are treatment options that make scientific sense and appear to stabilize the disease process, reduce deformity, and improve function. Offering no treatment at all will encourage our patients to pursue alternative treatments that may do harm, and misses the opportunity to do some good. Clearly, further work is necessary to develop safe and effective nonsurgical treatments for PD.

show abstract

“…Οι ίδιοι συγγραφείς σε επόµενη µελέτη [452] το 1997 η οποία σαν σκοπό είχε να διερευνήσει την προσαρµογή της δόσης του φαρµάκου, χορήγησαν 3000000 µονάδες ιντερφερόνης αλφα-2β, µε ένεση εντός της πλάκας, σε εβδοµαδιαία βάση, για τρεις εβδοµάδες σε 30 ασθενείς µε νόσο του Peyronie. Στην µελέτη αυτή 3 ασθενείς επιδεινώθηκαν και 10 καινούργιες πλάκες αναπτύχθηκαν.…”

Section: ιντερφερόνηunclassified

Αιμοδυναμικές Διαταραχές Στις Κάμψεις Του Πέους

Μπέκος¹

View full text Add to dashboard Cite

Local lnterferon-Alpha2b Is Not an Effective Treatment in Early-Stage Peyronie's Disease

Cited by 52 publications

References 17 publications

Peyronie’s Disease: Recent Treatment Modalities

Peyronie’s Disease: Recent Treatment Modalities

Peyronie's Disease: Evaluation and Review of Nonsurgical Therapy

Αιμοδυναμικές Διαταραχές Στις Κάμψεις Του Πέους

Contact Info

Product

Resources

About